vs
再生元制药（REGN）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
再生元制药的季度营收约是Bio-Techne的13.1倍（$3.9B vs $295.9M），再生元制药净利率更高（21.7% vs 12.8%，领先8.9%），再生元制药同比增速更快（2.5% vs -6.4%），过去两年再生元制药的营收复合增速更高（11.1% vs 4.2%）
再生元制药是一家总部位于美国纽约州韦斯特切斯特县的生物技术企业，成立于1988年。公司最初围绕神经营养因子及其再生能力开展研究，这也是其名称的由来，后续业务逐步拓展至细胞因子与酪氨酸激酶受体领域，首款产品为VEGF陷阱类药物。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
REGN vs TECH — 直观对比
营收规模更大
REGN
是对方的13.1倍
$295.9M
营收增速更快
REGN
高出8.9%
-6.4%
净利率更高
REGN
高出8.9%
12.8%
两年增速更快
REGN
近两年复合增速
4.2%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.9B | $295.9M |
| 净利润 | $844.6M | $38.0M |
| 毛利率 | — | 64.6% |
| 营业利润率 | 22.7% | 18.4% |
| 净利率 | 21.7% | 12.8% |
| 营收同比 | 2.5% | -6.4% |
| 净利润同比 | -8.0% | 68.3% |
| 每股收益（稀释后） | $7.78 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REGNTECH
| Q4 25 | $3.9B | $295.9M | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.7B | $317.0M | ||
| Q1 25 | $3.0B | $316.2M | ||
| Q4 24 | $3.8B | $297.0M | ||
| Q3 24 | $3.7B | $289.5M | ||
| Q2 24 | $3.5B | $306.1M | ||
| Q1 24 | $3.1B | $303.4M |
净利润REGNTECH
| Q4 25 | $844.6M | $38.0M | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.4B | $-17.7M | ||
| Q1 25 | $808.7M | $22.6M | ||
| Q4 24 | $917.7M | $34.9M | ||
| Q3 24 | $1.3B | $33.6M | ||
| Q2 24 | $1.4B | $40.6M | ||
| Q1 24 | $722.0M | $49.1M |
毛利率REGNTECH
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
营业利润率REGNTECH
| Q4 25 | 22.7% | 18.4% | ||
| Q3 25 | 27.3% | — | ||
| Q2 25 | 29.4% | -7.5% | ||
| Q1 25 | 19.5% | 12.2% | ||
| Q4 24 | 26.1% | 16.0% | ||
| Q3 24 | 31.7% | 13.8% | ||
| Q2 24 | 30.2% | 15.0% | ||
| Q1 24 | 23.9% | 22.1% |
净利率REGNTECH
| Q4 25 | 21.7% | 12.8% | ||
| Q3 25 | 38.9% | — | ||
| Q2 25 | 37.9% | -5.6% | ||
| Q1 25 | 26.7% | 7.1% | ||
| Q4 24 | 24.2% | 11.7% | ||
| Q3 24 | 36.0% | 11.6% | ||
| Q2 24 | 40.4% | 13.3% | ||
| Q1 24 | 23.0% | 16.2% |
每股收益（稀释后）REGNTECH
| Q4 25 | $7.78 | $0.24 | ||
| Q3 25 | $13.62 | — | ||
| Q2 25 | $12.81 | $-0.11 | ||
| Q1 25 | $7.27 | $0.14 | ||
| Q4 24 | $8.12 | $0.22 | ||
| Q3 24 | $11.54 | $0.21 | ||
| Q2 24 | $12.41 | $0.26 | ||
| Q1 24 | $6.27 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.6B | $172.9M |
| 总债务越低越好 | — | $260.0M |
| 股东权益账面价值 | $31.3B | $2.0B |
| 总资产 | $40.6B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资REGNTECH
| Q4 25 | $8.6B | $172.9M | ||
| Q3 25 | $8.4B | — | ||
| Q2 25 | $7.5B | $162.2M | ||
| Q1 25 | $8.3B | $140.7M | ||
| Q4 24 | $9.0B | $177.5M | ||
| Q3 24 | $9.8B | $187.5M | ||
| Q2 24 | $9.8B | $152.9M | ||
| Q1 24 | $10.5B | $145.3M |
总债务REGNTECH
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
股东权益REGNTECH
| Q4 25 | $31.3B | $2.0B | ||
| Q3 25 | $31.0B | — | ||
| Q2 25 | $29.9B | $1.9B | ||
| Q1 25 | $29.4B | $2.0B | ||
| Q4 24 | $29.4B | $2.1B | ||
| Q3 24 | $29.3B | $2.1B | ||
| Q2 24 | $28.2B | $2.1B | ||
| Q1 24 | $27.0B | $2.0B |
总资产REGNTECH
| Q4 25 | $40.6B | $2.5B | ||
| Q3 25 | $40.2B | — | ||
| Q2 25 | $38.2B | $2.6B | ||
| Q1 25 | $37.5B | $2.6B | ||
| Q4 24 | $37.8B | $2.7B | ||
| Q3 24 | $37.4B | $2.7B | ||
| Q2 24 | $36.1B | $2.7B | ||
| Q1 24 | $34.4B | $2.7B |
负债/权益比REGNTECH
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.2B | — |
| 自由现金流经营现金流 - 资本支出 | $922.0M | — |
| 自由现金流率自由现金流/营收 | 23.7% | — |
| 资本支出强度资本支出/营收 | 6.4% | — |
| 现金转化率经营现金流/净利润 | 1.39× | — |
| 过去12个月自由现金流最近4个季度 | $4.1B | — |
8季度趋势，按日历期对齐
经营现金流REGNTECH
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.1B | $98.2M | ||
| Q1 25 | $1.0B | $41.1M | ||
| Q4 24 | $1.3B | $84.3M | ||
| Q3 24 | $1.3B | $63.9M | ||
| Q2 24 | $354.0M | $75.5M | ||
| Q1 24 | $1.5B | $81.0M |
自由现金流REGNTECH
| Q4 25 | $922.0M | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $925.4M | $93.3M | ||
| Q1 25 | $815.8M | $31.0M | ||
| Q4 24 | $1.1B | $77.5M | ||
| Q3 24 | $1.0B | $54.7M | ||
| Q2 24 | $173.5M | $57.5M | ||
| Q1 24 | $1.4B | $64.5M |
自由现金流率REGNTECH
| Q4 25 | 23.7% | — | ||
| Q3 25 | 37.8% | — | ||
| Q2 25 | 25.2% | 29.4% | ||
| Q1 25 | 26.9% | 9.8% | ||
| Q4 24 | 28.1% | 26.1% | ||
| Q3 24 | 28.2% | 18.9% | ||
| Q2 24 | 4.9% | 18.8% | ||
| Q1 24 | 43.8% | 21.3% |
资本支出强度REGNTECH
| Q4 25 | 6.4% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 6.0% | 1.5% | ||
| Q1 25 | 7.6% | 3.2% | ||
| Q4 24 | 5.3% | 2.3% | ||
| Q3 24 | 6.5% | 3.2% | ||
| Q2 24 | 5.1% | 5.9% | ||
| Q1 24 | 4.3% | 5.4% |
现金转化率REGNTECH
| Q4 25 | 1.39× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 1.29× | 1.82× | ||
| Q4 24 | 1.38× | 2.42× | ||
| Q3 24 | 0.96× | 1.90× | ||
| Q2 24 | 0.25× | 1.86× | ||
| Q1 24 | 2.09× | 1.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REGN
暂无分部数据
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
